How does Canaloplasty compare to other glaucoma treatments in terms of IOP Lowering benefits and average medication? Here’s a summary from Dr. Douglas J. Rhee’s talk given on April 13, 2018 during the ASCRS 2018 Glaucoma Day “Is Trabeculectomy Dead?” session, titled “NO, It’s Alive and Well!”
This is a developing article. We will eventually add more information to include other important aspects such as long term studies, risks and complications, insurance coverage, and etc. Please subscribe to our newsletter (see sidebar) to get email updates on this topic.
Procedure
IOP
Medication
Trabeculectomy
17.5 mmHg
14.5 mmHg
Trabectome vs Trabeculectomy
16.6 mmHg
10.0 mmHg
2.3
0.4
Canaloplasty vs
Trabeculectomy
13.8 mmHg
11.6 mmHg
0.6
0.2
iStent + Cataract Surgery
17.1 mmHg
0.3
GATT (Gonioscopy-Assisted Transluminal Trabeculotomy)
Phakic POAG GATT
GATT + Cataract Surgery
15.7 mmHg
16.2 mmHg
1.5
1.0
CyPass and Cataract Surgery
Cypass + Cataract
Cataract Alone
17.1 mmHg
19.0 mmHg
0.2
0.6
Xen c MMC
15.9 mmHg
1.7
Tube Shunts vs. Trabeculectomy
Tube (Baerveldt)
Trabeculectomy
13.8 mmHg
12.4 mmHg
2.1
0.9
David Richardson, MD
Medical Director, San Marino Eye
David Richardson, M.D. is recognized as one of the top cataract and glaucoma surgeons in the US and is among an elite group of glaucoma surgeons in the country performing the highly specialized canaloplasty procedure. Morever, Dr. Richardson is one of only a few surgeons in the greater Los Angeles area that performs MicroPulse P3™ "Cyclophotocoagulation" (MP3) glaucoma laser surgery. Dr. Richardson graduated Magna Cum Laude from the University of Southern California and earned his Medical Degree from Harvard Medical School. He completed his ophthalmology residency at the LAC+USC Medical Center/ Doheny Eye Institute. Dr. Richardson is also an Ambassador of Glaucoma Research Foundation.
